Mark Crossley - INDIVIOR PLC CFO, Director

INVVYDelisted Stock  USD 21.85  0.20  0.92%   

Director

Mr. Mark Crossley serves as Chief Financial Officer, Executive Director of the Company. Indivior Chief Strategy Officer, Reckitt Benckiser Pharmaceuticals Inc. Global Finance Director, Procter and Gamble Associate Director Corporationrationrate Portfolio Finance, Procter and Gamble Associate Director Female Beauty Strategy and Business Planning, National Association of Corporationrationrate Directors Board Leadership Fellow. since 2017.
Tenure 7 years
Phone804 379 1090
Webhttps://www.indivior.com

INDIVIOR PLC Management Efficiency

The company has return on total asset (ROA) of 0.0697 % which means that it generated a profit of $0.0697 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.8557 %, meaning that it generated $0.8557 on every $100 dollars invested by stockholders. INDIVIOR PLC's management efficiency ratios could be used to measure how well INDIVIOR PLC manages its routine affairs as well as how well it operates its assets and liabilities.
INDIVIOR PLC ADR has accumulated 239 M in total debt with debt to equity ratio (D/E) of 1.22, which is about average as compared to similar companies. INDIVIOR PLC ADR has a current ratio of 1.67, which is within standard range for the sector. Debt can assist INDIVIOR PLC until it has trouble settling it off, either with new capital or with free cash flow. So, INDIVIOR PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like INDIVIOR PLC ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for INDIVIOR to invest in growth at high rates of return. When we think about INDIVIOR PLC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

John BilbreyElanco Animal Health
64
John GreischCatalent
65
Michael BarberCatalent
60
Breno OliveiraHypera SA
40
Rolf ClassonCatalent
75
Gregory LucierCatalent
56
Rosemary CraneCatalent
60
Kirk McDonaldElanco Animal Health
54
Matt RoacheIronwood Pharmaceuticals
N/A
David RicksElanco Animal Health
52
Kapila AnandElanco Animal Health
67
Denise ScotsKnightElanco Animal Health
61
Lawrence KurziusElanco Animal Health
63
Madhavan BalachandranCatalent
69
Christa KreuzburgCatalent
61
Peter ZippeliusCatalent
41
Art GarciaElanco Animal Health
59
Jack StahlCatalent
67
Michael HarringtonElanco Animal Health
58
Joshua SmileyElanco Animal Health
50
William DoyleElanco Animal Health
58
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. Indivior Plc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 885 people. INDIVIOR PLC ADR [INVVY] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

INDIVIOR PLC ADR Leadership Team

Elected by the shareholders, the INDIVIOR PLC's board of directors comprises two types of representatives: INDIVIOR PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of INDIVIOR. The board's role is to monitor INDIVIOR PLC's management team and ensure that shareholders' interests are well served. INDIVIOR PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, INDIVIOR PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jon Fogle, Chief Human Resource Officer
Nina DeLorenzo, Chief Officer
Jeffrey Burris, Chief Officer
Jason Thompson, VP Relations
Christian Heidbreder, Chief Scientific Officer
Richard Simkin, Chief Commercial and Strategy Officer
Ryan Preblick, CFO Director
Mark Crossley, CFO, Director
Hillel West, Chief Officer
Cynthia Cetani, Chief Officer

INDIVIOR Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is INDIVIOR PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Consideration for investing in INDIVIOR Pink Sheet

If you are still planning to invest in INDIVIOR PLC ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the INDIVIOR PLC's history and understand the potential risks before investing.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences